Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 353

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Elesclomol induces cancer cell apoptosis through oxidative stress

Open access
Kirshner, Jessica R., He, Suqin, Balasubramanyam, Vishwasenani, Kepros, Jane, Yang, Chin-Yu, Zhang, Mei, Du, Zhenjian, Barsoum, James, Bertin, John·2008·Molecular Cancer Therapeutics

Abstract

Elesclomol (formerly STA-4783) is a novel small molecule undergoing clinical evaluation in a pivotal phase III melanoma trial (SYMMETRY). In a phase II randomized, double-blinded, controlled, multi-center trial in 81 patients with stage IV metastatic melanoma, treatment with elesclomol plus paclitaxel showed a statistically significant doubling of progression-free survival time compared with treatment with paclitaxel alone. Although elesclomol displays significant therapeutic activity in the clinic, the mechanism underlying its anticancer activity has not been defined previously. Here, we show that elesclomol induces apoptosis in cancer cells through the induction of oxidative stress. Treatment of cancer cells in vitro with elesclomol resulted in the rapid generation of reactive oxygen species (ROS) and the induction of a transcriptional gene profile characteristic of an oxidative stress response. Inhibition of oxidative stress by the antioxidant N-acetylcysteine blocked the induction of gene transcription by elesclomol. In addition, N-acetylcysteine blocked drug-induced apoptosis, indicating that ROS generation is the primary mechanism responsible for the proapoptotic activity of elesclomol. Excessive ROS production and elevated levels of oxidative stress are critical biochemical alterations that contribute to cancer cell growth. Thus, the induction of oxidative stress by elesclomol exploits this unique characteristic of cancer cells by increasing ROS levels beyond a threshold that triggers cell death. [Mol Cancer Ther 2008;7(8):2319–27]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-08-0298

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 353

Metadata

Authors
Kirshner, J. R., He, S., Balasubramanyam, V., Kepros, J., Yang, C.-Y., Zhang, M., Du, Z., Barsoum, J., & Bertin, J.
Venue
Molecular Cancer Therapeutics
Published
2008-08-01
Volume
7
Issue
8
Pages
2319-2327
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2140464899
Cited by
353
References
36
FWCI
4.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elesclomol induces cancer cell apoptosis through oxidative stress. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0298
The paper
Kirshner, J. R., He, S., Balasubramanyam, V., Kepros, J., Yang, C.-Y., Zhang, M., Du, Z., Barsoum, J., & Bertin, J. (2008). Elesclomol induces cancer cell apoptosis through oxidative stress. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.